Ma ʻAukake 22, 2025, ua loaʻa iā Datopotamab deruxtecan (Dato-DXd; Datroway) ka ʻāpono ma Kina no ka mālama ʻana i nā poʻe maʻi makua me ka unresectable a i ʻole metastatic hormone receptor–positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, a i ʻole IHC 2+/in situ hybridization [ISH] negative) ka maʻi ʻaʻai umauma i loaʻa mua i ka lāʻau endocrine a me ka liʻiliʻi he 1 laina o ka chemotherapy ma ke ʻano holomua.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
Ua hoʻokumu ʻia kēia ʻae ʻia ma nā hopena maikaʻi o ke aʻo honua Phase III TROPION-Breast01. Ua loiloi ke aʻo honua, phase 3, open-label, randomized TROPION-Breast01 i ka trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus ke koho a ka mea noiʻi o ka chemotherapy (ICC) i ka hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) ka maʻi ʻaʻai umauma.
Ua hoʻokaʻawale ʻia nā maʻi iā Dato-DXd (n = 365) a i ʻole ICC (n = 367). Ua hōʻemi nui ʻo Dato-DXd i ka pilikia o ka holomua a i ʻole ka make e kūʻē i ka ICC (PFS e ka BICR hazard ratio [HR], 0.63 [95% CI, 0.52 a i 0.76]; P < .0001). Ua ʻike ʻia ka pōmaikaʻi PFS kūlike ma waena o nā hui liʻiliʻi. ʻOiai ʻaʻole i oʻo ka ʻikepili OS, ua ʻike ʻia kahi ʻano e makemake ana iā Dato-DXd (HR, 0.84 [95% CI, 0.62 a i 1.14]). ʻOi aku ka haʻahaʻa o ka helu o nā hanana ʻino e pili ana i ka lāʻau lapaʻau (TRAEs) me Dato-DXd ma mua o ICC (20.8% v 44.7%). ʻO nā TRAE maʻamau (kēlā me kēia pae; pae ≥3) ʻo ia ka nausea (51.1%; 1.4%) a me ka stomatitis (50%; 6.4%) me Dato-DXd a me neutropenia (huaʻōlelo i hui pū ʻia, 42.5%; 30.8%) me ICC.
ʻO nā maʻi e loaʻa ana iā Dato-DXd he hoʻomaikaʻi koʻikoʻi a koʻikoʻi hoʻi i ka PFS a me kahi ʻano palekana maikaʻi a hiki ke hoʻokele ʻia, ke hoʻohālikelike ʻia me ICC.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
Ka manawa hoʻouna: ʻAukake-26-2025